Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade

Chia Sheng Yen, Jung Chien Chen, Yi Fang Chang, Ya Fen Hsu, Pei Ting Chiu, Ching Shiue, Yu Fan Chuang, George Ou, Ming Jen Hsu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Statins are used widely to lower serum cholesterol and the incidence of cardiovascular diseases. Growing evidence shows that statins also exhibit beneficial effects against cancers. In this study, we investigated the molecular mechanisms involved in lovastatin-induced cell death in Fadu hypopharyngeal carcinoma cells. Lovastatin caused cell cycle arrest and apoptosis in FaDu cells. Lovastatin increased p21 cip/Waf1 level while the survivin level was decreased in the presence of lovastatin. Survivin siRNA reduced cell viability and induced cell apoptosis in FaDu cells. Lovastatin induced phosphorylation of AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK) and transcription factor p63. Lovastatin also caused p63 acetylation and increased p63 binding to survivin promoter region in FaDu cells. AMPK-p38MAPK signaling blockade abrogated lovastatin-induced p63 phosphorylation. Lovastatin's enhancing effect on p63 acetylation was reduced in HDAC3- or HDAC4- transfected cells. Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin's effects on p21 cip/Waf1 and survivin. Furthermore, lovastatin inhibited subcutaneous FaDu xenografts growth in vivo. Taken together, lovastatin may activate AMPK-p38MAPK-p63-survivin cascade to cause FaDu cell death. This study establishes, at least in part, the signaling cascade by which lovastatin induces hypopharyngeal carcinoma cell death.

Original languageEnglish
Article number25082
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Apr 28 2016

Fingerprint

Lovastatin
AMP-Activated Protein Kinases
Cell Death
Carcinoma
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Acetylation
Small Interfering RNA
Phosphorylation
Apoptosis
p38 Mitogen-Activated Protein Kinases
Cell Cycle Checkpoints
Heterografts
Genetic Promoter Regions
Transfection
Cell Survival
Transcription Factors
Cardiovascular Diseases

ASJC Scopus subject areas

  • General

Cite this

Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. / Yen, Chia Sheng; Chen, Jung Chien; Chang, Yi Fang; Hsu, Ya Fen; Chiu, Pei Ting; Shiue, Ching; Chuang, Yu Fan; Ou, George; Hsu, Ming Jen.

In: Scientific Reports, Vol. 6, 25082, 28.04.2016.

Research output: Contribution to journalArticle

Yen, Chia Sheng ; Chen, Jung Chien ; Chang, Yi Fang ; Hsu, Ya Fen ; Chiu, Pei Ting ; Shiue, Ching ; Chuang, Yu Fan ; Ou, George ; Hsu, Ming Jen. / Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. In: Scientific Reports. 2016 ; Vol. 6.
@article{4e5bcf9510f345829201fde87831c535,
title = "Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade",
abstract = "Statins are used widely to lower serum cholesterol and the incidence of cardiovascular diseases. Growing evidence shows that statins also exhibit beneficial effects against cancers. In this study, we investigated the molecular mechanisms involved in lovastatin-induced cell death in Fadu hypopharyngeal carcinoma cells. Lovastatin caused cell cycle arrest and apoptosis in FaDu cells. Lovastatin increased p21 cip/Waf1 level while the survivin level was decreased in the presence of lovastatin. Survivin siRNA reduced cell viability and induced cell apoptosis in FaDu cells. Lovastatin induced phosphorylation of AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK) and transcription factor p63. Lovastatin also caused p63 acetylation and increased p63 binding to survivin promoter region in FaDu cells. AMPK-p38MAPK signaling blockade abrogated lovastatin-induced p63 phosphorylation. Lovastatin's enhancing effect on p63 acetylation was reduced in HDAC3- or HDAC4- transfected cells. Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin's effects on p21 cip/Waf1 and survivin. Furthermore, lovastatin inhibited subcutaneous FaDu xenografts growth in vivo. Taken together, lovastatin may activate AMPK-p38MAPK-p63-survivin cascade to cause FaDu cell death. This study establishes, at least in part, the signaling cascade by which lovastatin induces hypopharyngeal carcinoma cell death.",
author = "Yen, {Chia Sheng} and Chen, {Jung Chien} and Chang, {Yi Fang} and Hsu, {Ya Fen} and Chiu, {Pei Ting} and Ching Shiue and Chuang, {Yu Fan} and George Ou and Hsu, {Ming Jen}",
year = "2016",
month = "4",
day = "28",
doi = "10.1038/srep25082",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade

AU - Yen, Chia Sheng

AU - Chen, Jung Chien

AU - Chang, Yi Fang

AU - Hsu, Ya Fen

AU - Chiu, Pei Ting

AU - Shiue, Ching

AU - Chuang, Yu Fan

AU - Ou, George

AU - Hsu, Ming Jen

PY - 2016/4/28

Y1 - 2016/4/28

N2 - Statins are used widely to lower serum cholesterol and the incidence of cardiovascular diseases. Growing evidence shows that statins also exhibit beneficial effects against cancers. In this study, we investigated the molecular mechanisms involved in lovastatin-induced cell death in Fadu hypopharyngeal carcinoma cells. Lovastatin caused cell cycle arrest and apoptosis in FaDu cells. Lovastatin increased p21 cip/Waf1 level while the survivin level was decreased in the presence of lovastatin. Survivin siRNA reduced cell viability and induced cell apoptosis in FaDu cells. Lovastatin induced phosphorylation of AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK) and transcription factor p63. Lovastatin also caused p63 acetylation and increased p63 binding to survivin promoter region in FaDu cells. AMPK-p38MAPK signaling blockade abrogated lovastatin-induced p63 phosphorylation. Lovastatin's enhancing effect on p63 acetylation was reduced in HDAC3- or HDAC4- transfected cells. Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin's effects on p21 cip/Waf1 and survivin. Furthermore, lovastatin inhibited subcutaneous FaDu xenografts growth in vivo. Taken together, lovastatin may activate AMPK-p38MAPK-p63-survivin cascade to cause FaDu cell death. This study establishes, at least in part, the signaling cascade by which lovastatin induces hypopharyngeal carcinoma cell death.

AB - Statins are used widely to lower serum cholesterol and the incidence of cardiovascular diseases. Growing evidence shows that statins also exhibit beneficial effects against cancers. In this study, we investigated the molecular mechanisms involved in lovastatin-induced cell death in Fadu hypopharyngeal carcinoma cells. Lovastatin caused cell cycle arrest and apoptosis in FaDu cells. Lovastatin increased p21 cip/Waf1 level while the survivin level was decreased in the presence of lovastatin. Survivin siRNA reduced cell viability and induced cell apoptosis in FaDu cells. Lovastatin induced phosphorylation of AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK) and transcription factor p63. Lovastatin also caused p63 acetylation and increased p63 binding to survivin promoter region in FaDu cells. AMPK-p38MAPK signaling blockade abrogated lovastatin-induced p63 phosphorylation. Lovastatin's enhancing effect on p63 acetylation was reduced in HDAC3- or HDAC4- transfected cells. Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin's effects on p21 cip/Waf1 and survivin. Furthermore, lovastatin inhibited subcutaneous FaDu xenografts growth in vivo. Taken together, lovastatin may activate AMPK-p38MAPK-p63-survivin cascade to cause FaDu cell death. This study establishes, at least in part, the signaling cascade by which lovastatin induces hypopharyngeal carcinoma cell death.

UR - http://www.scopus.com/inward/record.url?scp=84964851648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964851648&partnerID=8YFLogxK

U2 - 10.1038/srep25082

DO - 10.1038/srep25082

M3 - Article

C2 - 27122225

AN - SCOPUS:84964851648

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 25082

ER -